MARKET

BOLT

BOLT

Bolt Biotherapeutics, Inc.
NASDAQ
0.4051
-0.0136
-3.25%
Opening 12:51 03/14 EDT
OPEN
0.4120
PREV CLOSE
0.4187
HIGH
0.4126
LOW
0.4030
VOLUME
17.47K
TURNOVER
--
52 WEEK HIGH
1.560
52 WEEK LOW
0.4015
MARKET CAP
15.50M
P/E (TTM)
-0.2371
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BOLT last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at BOLT last week (0224-0228)?
Weekly Report · 03/03 09:07
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 02/27 22:15
Weekly Report: what happened at BOLT last week (0217-0221)?
Weekly Report · 02/24 09:07
Weekly Report: what happened at BOLT last week (0210-0214)?
Weekly Report · 02/17 09:07
Bolt Biotherapeutics provides update on co-development collaboration with Toray
TipRanks · 02/11 21:45
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
Barchart · 02/11 15:05
Weekly Report: what happened at BOLT last week (0203-0207)?
Weekly Report · 02/10 09:06
More
About BOLT
More
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Recently
Symbol
Price
%Change

Webull offers Bolt Biotherapeutics Inc stock information, including NASDAQ: BOLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BOLT stock methods without spending real money on the virtual paper trading platform.